Pharma BD Deal Intelligence
Zacks framed the $925M acquisition as a sound strategic fit that meaningfully expanded LabCorp's reproductive, hematology-oncology, and clinical-trials…
The FTC challenged a separate LabCorp acquisition (Westcliff) the same year, signaling regulatory scrutiny of the duopolistic LabCorp/Quest market position…
LabCorp confirmed close on December 1, 2010, citing immediate accretion to esoteric/molecular testing capacity and ~$795M net cash cost after tax benefits.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
LabCorp agreed to acquire Genzyme's Genetics business for $925M cash. 2009 revenue ~$371M with 9 testing labs and ~1,900 employees. Closed December 1, 2010.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Laboratory Corporation of America Holdings / Genzyme Genetics (business unit) (this deal) | 2010 | $925M | 68 |
| Laboratory Corporation of America Holdings / OPKO Health, Inc. | 2025 | $225M | — |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
| Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. | 2016 | $17.6B | 91 |
| DPx Holdings B.V. (JLL Partners 51% / Royal DSM 49%) / Patheon Inc. + DSM Pharmaceutical Products | 2013 | $2.6B | 90 |
← Browse all deals · How we score deals
More: 2010 deals · Other deals